Trial Profile
A Randomized Multicenter Ib/II Study to Assess the Safety & Immunological Effect of Chemoradiation Therapy in Combination With Pembrolizumab Compared to CRT Alone Resectable/Borderline Resectable Pancreatic Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Capecitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms UVA-PC-PD101
- 08 Jun 2021 The study was amended after enrollment of 37 patients to allow FOLFIRINOX prior to CRT, given changes in standard of care as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Preliminary results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 15 Nov 2020 Planned number of patients changed from 56 to 68.